Cathepsin K deficiency in mice induces structural and metabolic changes in the central nervous system that are associated with learning and memory deficits
- Stephanie Dauth†1,
- Ruxandra F Sîrbulescu†1, 3,
- Silvia Jordans1, 4,
- Maren Rehders1,
- Linda Avena1,
- Julia Oswald1,
- Alexander Lerchl1,
- Paul Saftig2 and
- Klaudia Brix1Email author
© Dauth et al; licensee BioMed Central Ltd. 2011
Received: 15 April 2011
Accepted: 27 July 2011
Published: 27 July 2011
Cathepsin K is a cysteine peptidase known for its importance in osteoclast-mediated bone resorption. Inhibitors of cathepsin K are in clinical trials for treatment of osteoporosis. However, side effects of first generation inhibitors included altered levels of related cathepsins in peripheral organs and in the central nervous system (CNS). Cathepsin K has been recently detected in brain parenchyma and it has been linked to neurobehavioral disorders such as schizophrenia. Thus, the study of the functions that cathepsin K fulfils in the brain becomes highly relevant.
Cathepsin K messenger RNA was detectable in all brain regions of wild type (WT) mice. At the protein level, cathepsin K was detected by immunofluorescence microscopy in vesicles of neuronal and non-neuronal cells throughout the mouse brain. The hippocampus of WT mice exhibited the highest levels of cathepsin K activity in fluorogenic assays, while the cortex, striatum, and cerebellum revealed significantly lower enzymatic activities. At the molecular level, the proteolytic network of cysteine cathepsins was disrupted in the brain of cathepsin K-deficient (Ctsk-/-) animals. Specifically, cathepsin B and L protein and activity levels were altered, whereas cathepsin D remained largely unaffected. Cystatin C, an endogenous inhibitor of cysteine cathepsins, was elevated in the striatum and hippocampus, pointing to regional differences in the tissue response to Ctsk ablation. Decreased levels of astrocytic glial fibrillary acidic protein, fewer and less ramified profiles of astrocyte processes, differentially altered levels of oligodendrocytic cyclic nucleotide phosphodiesterase, as well as alterations in the patterning of neuronal cell layers were observed in the hippocampus of Ctsk-/- mice. A number of molecular and cellular changes were detected in other brain regions, including the cortex, striatum/mesencephalon, and cerebellum. Moreover, an overall induction of the dopaminergic system was found in Ctsk-/- animals which exhibited reduced anxiety levels as well as short- and long-term memory impairments in behavioral assessments.
We conclude that deletion of the Ctsk gene can lead to deregulation of related proteases, resulting in a wide range of molecular and cellular changes in the CNS with severe consequences for tissue homeostasis. We propose that cathepsin K activity has an important impact on the development and maintenance of the CNS in mice.
Cathepsin K is a mammalian cysteine peptidase that is sorted to endo-lysosomes and secreted into the extracellular space by certain cell types . It is abundant in osteoclasts and has a prominent role in bone remodeling due to its collagenolytic activity . Indeed, cathepsin K deficiency has been linked to bone disorders such as pycnodysostosis and osteopetrosis [3, 4], while the excessive activity of this enzyme may lead to osteoporosis , making it a likely target for rational drug design [6–8]. Cathepsin K has also been identified in a variety of cell types other than osteoclasts, such as macrophages , bronchial and alveolar epithelia , gastrointestinal mucosa , and thyroid epithelia [8, 12, 13], indicating that its distribution and functions may not be as clearly defined as initially thought. In the human brain, cathepsin K has been shown to be present in the choroid plexus , and recent studies have demonstrated its widespread distribution within neurons and glial cells .
To date, cathepsin K distribution and functions in the mouse CNS are largely unknown, however Ctsk-/- mice have not been reported to suffer from severe neurobehavioral phenotypes . The phenomenon of compensation, i.e. upregulation of related cysteine proteases, has been suggested to explain the mild phenotypes of mice with single deficiencies in cysteine cathepsins [1, 16]. For example, enzyme compensation has been previously observed in the thyroid of Ctsk-/- mice, where cathepsin L is significantly upregulated , as well as in the brain of Ctsd-/- mice, where elevated levels of cathepsin B have been detected . Moreover, the absence of cathepsins B and L is known to carry dramatic consequences, including neurodegeneration and brain atrophy [18, 19], while the impact of cathepsin K deficiency on the mouse CNS has not been investigated in sufficient detail to date.
Interestingly, basic cathepsin K inhibitors previously tested in clinical trials have been reported to increase the activity levels of cathepsins B and L not only in the liver, kidney and spleen, but also in the CNS of rats , indicating that risk assessments of potential side effects of cathepsin inhibitor treatments must consider changes in the proteolytic network of both peripheral organs and the CNS . Several pathways by which systemically reduced cathepsin K activity could cause alterations at the level of the brain are plausible: a direct effect on the metabolism of neurons and glial cells, via modulation of related enzymes, and/or indirectly, via yet unknown pathways.
In the present study, we used reverse transcription polymerase chain reaction (RT-PCR), immunolabeling, and enzyme histochemistry to demonstrate the expression of cathepsin K in the mouse brain, both at the mRNA and at the protein level. Moreover, cathepsin K activity assays revealed that specific enzyme activity in the hippocampus was higher than in other brain regions investigated. Therefore, we used Ctsk-/- mice to investigate the systemic impact of cathepsin K gene ablation on the structure and metabolism of the brain. Immunoblotting and proteolytic activity assays were employed in WT and Ctsk-/- mice to determine activity levels of related aspartic and cysteine cathepsins with an established function in the mouse CNS, and to assess the levels of a main endogenous cysteine cathepsin inhibitor, cystatin C. We further addressed the status of major brain regions including the cerebral cortex, the mesostriatal complex, the hippocampus, and the cerebellum, by using immunoblotting and immunohistochemistry to evaluate molecular markers of neuronal and glial cells. Potential behavioral alterations were analyzed in a series of tests chosen to monitor locomotor activity, anxiety levels, as well as spatial and non-spatial learning and memory.
Our results indicate that learning and memory impairments in Ctsk-/- mice correlated with a combination of alterations in proteolytic pathways, including significant reductions of cathepsin B and L levels in cortex and striatum as well as increased cystatin C levels in striatum and hippocampus. In addition, some of the most striking observations included immature astrocytes in hippocampal regions of Ctsk-/- animals, significant alterations in neuronal synaptotagmin levels, and prominent changes in the cyclic nucleotide phosphodiesterase (CNPase) levels of oligodendrocytes, indicating a major influence of cathepsin K on the cellular metabolism and function in the mouse CNS. In further support of this conclusion, a significantly altered distribution and patterning of neurons was observed throughout the hippocampus of Ctsk-/- mice. We propose that the systemic disruption of cathepsin K activity during development and adulthood has severe local impacts on the structural integrity of the mouse CNS, eventually resulting in functional impairments such as learning and memory deficits.
Cathepsin K identification in the mouse CNS
In order to further verify the specificity of the observed immunofluorescence and cathepsin K substrate conversion reactions, brain tissue homogenates prepared from WT and Ctsk-/- mice were used to perform cathepsin K activity assays, employing Abz-HPGGPQ-EDN2pH as a fluorogenic substrate  (Figure 2C - 2F). Cathepsin K activity was detected in all analyzed brain regions of WT mice (Figure 2C - 2F, open bars), whereas no activity was detectable in extracts from brain tissue of Ctsk-/- animals (grey bars). Importantly, specific cathepsin K activity reached highest levels in the hippocampus, while the cortex, striatum/mesencephalon, and the cerebellum exhibited significantly lower cathepsin K activity in WT mice (Figure 2C - 2F, open bars).
These results indicated cathepsin K expression and suggested its enzymatic functionality throughout the mouse CNS. Hence, we analyzed the impact of cathepsin K deficiency on different regions of the mouse brain at the molecular and cellular level.
Impact of cathepsin K deficiency on the proteolytic network of related cathepsins in the mouse CNS
It is known that cathepsin networks are able to compensate for the loss of function of individual enzymes. If the activity of a given cathepsin is inhibited, either chemically or through gene ablation, related cathepsins might be upregulated in a cell type- and tissue-specific manner. In order to investigate such potential network effects induced by the loss of cathepsin K, the protein and activity levels of cathepsins B, D, and L and the protein levels of the endogenous cysteine peptidase inhibitor cystatin C were determined by immunoblotting and proteolytic activity assays in tissue extracts prepared from different regions of the CNS of WT and Ctsk-/- mice.
Cathepsin D protein levels were not altered significantly in any of the investigated brain regions (Additional file 1 and Additional file 2). These results suggested that the aspartic cathepsin D is not affected by cathepsin K deficiency. By contrast, protein levels of cathepsins B (p < 0.001) and L (p < 0.05) (Additional file 1 and Additional file 2) were significantly reduced in cerebral cortex of Ctsk-/- compared to WT mice, although no significant differences were observed in the activity levels. The expression levels of the endogenous inhibitor cystatin C were not altered (Additional file 1). In the striatum/mesencephalon a significant decrease in the enzymatic activity of both cathepsins B (p < 0.001) and L (p < 0.05) was observed while cystatin C levels were increased (p < 0.05) in this brain region (Additional file 1). Cathepsin B protein and activity levels remained unaffected in the cerebellum and hippocampus of Ctsk-/- mice (Additional file 1). Cathepsin L activity levels were slightly but not significantly reduced in cerebellum and hippocampus, although cathepsin L protein levels were increased in the hippocampus (p < 0.05; Additional file 1). As in the striatum/mesencephalon, an increase of cystatin C protein levels (p < 0.001) was observed in the hippocampus of Ctsk-/- when compared to WT mice (Additional file 1). Overall, these results indicate a deregulated proteolytic network within various regions of the Ctsk-/- mouse brain, affecting in particular cysteine cathepsins.
Impact of cathepsin K deficiency on neuronal markers and cytoarchitecture in the hippocampus
Immunohistochemical identification of NeuN-positive neuronal nuclei in serial cryo-sections and semi-automated pattern analyses revealed significant differences in the overall distribution of neurons in all investigated areas in the dorsal and ventral hippocampus of Ctsk-/- mice in comparison to WT (p < 0.001, two-sample Kolmogorov-Smirnov test). Neurons were identified and counted using image analysis software (CellProfiler 2.0, version 9777). In order to analyze neuronal patterning, the number of neighbours per neuron within a radius of 7 μm or lower was initially determined. Patterning was interpreted as dense when neurons were surrounded by many neighbours, while a sparse patterning was indicated by a predominance of neurons surrounded by few neighbours. For instance, typical patterning in WT mice in the DG was characterized by most neurons having 5 neighbours in dorsal versus 6-7 neighbours in ventral hippocampus (Figure 3C and 3I, respectively, white bars).
The dorsal DG of Ctsk-/- mice showed a more densely packed distribution of neurons, with numerous neurons surrounded by many neighbours, whereas the opposite was true for WT mice, in which most neurons had relatively few neighbours (Figure 3C). This different patterning in Ctsk-/- mice was most obvious when comparing the shifts in the maxima of bell-shaped curves profiling the numbers of neuronal neighbours to those in WT animals (Figure 3, straight lines profiling white bars versus dotted lines profiling grey bars). This difference - more densely packed neurons in Ctsk-/- mice - was observed in all investigated areas of the dorsal hippocampus (Figure 3C - 3F). Counting also revealed a significant increase in the numbers of NeuN-positive cells in the dorsal DG, CA3, and CA2 regions of Ctsk-/- compared to WT mice (Figure 3B; p < 0.001; p < 0.05 and p < 0.001, respectively). A slight, but significant reduction of NeuN-positive cell nuclei was observed in the dorsal CA1 region of Ctsk-/- mice (Figure 3B; p < 0.001).
In contrast to the dorsal part, the ventral hippocampus showed strikingly different alterations in neuronal numbers and distribution in consequence of cathepsin K deficiency. WT animals exhibited more densely packed neurons in the ventral hippocampus, whereas Ctsk-/- mice had more neurons with fewer neighbours in all investigated areas. This is indicative of increased neuronal spreading in the ventral hippocampus of Ctsk-/- animals (Figure 3I - 3L). These alterations were most obvious in the DG, although the overall neuronal patterning was significantly different in all areas of the ventral hippocampus between the two genotypes. Furthermore, the numbers of NeuN-positive cells in the ventral DG and CA1 regions of Ctsk-/- mice were significantly decreased as compared to WT controls (Figure 3H; p < 0.001).
Overall, these results suggest subtle changes in the cytoarchitecture of the hippocampus of Ctsk-/- mice, with a gain of neurons in its dorsal part at the expense of a loss of neurons in its ventral part. Furthermore, a denser packing of neurons was observed in dorsal hippocampal regions, whereas neurons had a sparser distribution in the ventral hippocampus of Ctsk-/- mice.
Impact of cathepsin K deficiency on glial cells
Behavioral effects of cathepsin K deficiency
Diurnal variations of in-cage activities of 5 animals per each genotype were determined over a time period of 3 weeks by a motion-triggered infrared sensor module. No significant alterations in frequencies of day or night activities were detectable (Additional file 3), arguing against any overt deficits in locomotor function of Ctsk-/- mice up to an age of 6 months. In an elevated plus maze task Ctsk-/- mice spent approximately 36% (108s out of 300s) in the open arms, whereas WT mice spent only about 19% (57s out of 300s) of total time in this area. Correspondingly, while the WT mice showed a pronounced preference for the closed arms of the maze (p < 0.001), in Ctsk-/- mice this difference was not detectable (Additional file 4). Moreover, a hole board test revealed a significant increase in the frequency of central area crossing in Ctsk-/- mice, supporting the hypothesis of reduced anxiety in this genotype (Additional file 4).
In order to test long-term non-spatial memory, a novel object recognition test was used. This assessment included two habituation sessions and a test session, when a familiar object was replaced with a novel one. During the final test session of the novel object recognition test WT mice spent significantly (p < 0.01) more time exploring the novel object than they spent with any of the familiar objects (Figure 8A and 8B, white bars). By contrast, Ctsk-/- mice did not show any preference for the new object over the familiar ones, indicating that they could not discriminate the novel element placed in their familiar environment (Figure 8A and 8B, grey bars). Interestingly, during all sessions Ctsk-/- mice made overall more direct contacts with all objects as compared to WT animals (data not shown), again indicating decreased inhibition levels.
To further investigate a potential learning deficit of Ctsk-/- mice, an elevated multiple choice maze was used (Figure 8C), which allowed the testing of both short-term (working memory, WM) and long-term learning and memory proficiency (reference memory, RM). A repeated measures ANOVA, with test day as 'within subjects factor' and genotype as 'between subjects factor', indicated that Ctsk-/- mice made significantly more reference memory errors (F(1,21) = 46.981, p < 0.0001) as well as working memory errors (F(1,21) = 60.273, p < 0.0001), as compared to WT mice (Figure 8D and 8E). As illustrated in Figures 8D and 8E, subsequent pairwise comparisons indicated a clear separation in performance levels for the two genotypes starting from day two (WM) or day five (RM). While WT mice displayed a normal learning curve with progressively fewer errors, Ctsk-/- mice showed almost no improvement over the duration of the experiment.
Cathepsin K and the dopaminergic system
Until recently, the expression of cathepsin K was believed to be limited to osteoclasts, where it serves a central function for the proper turnover of long bones [2–4]. Cathepsin K expression has since been shown in a variety of organs and tissues, and has been connected to numerous other functions, such as proper signalling in the context of the immune response  or the processing of β-endorphin in the brain . Cathepsin K has also been associated with diseases, such as breast cancer  and schizophrenia . Further functions of cathepsin K with a widespread impact on physiology and pathophysiology comprise its contributions in glucose metabolism  and in the processing of one of its natural substrates, thyroglobulin, thereby mediating liberation of thyroid hormones [8, 12, 13, 16]. Hence, more detailed investigations concerning other potential roles of this protease are essential, especially considering the entry of cathepsin K inhibitors into clinical treatment of osteoporosis [7, 8, 34]. The present study aimed to characterize possible functions of cathepsin K in the mouse CNS. Our results demonstrate that cathepsin K is of considerably higher importance for the development, structure, and function of the CNS than previously thought.
From the results of this study, we concluded that the metabolism and structure of non-neuronal cells were significantly perturbed in the CNS of Ctsk-/- animals. The numbers and the maturation level of astrocytes were decreased in the hippocampus, while oligodendrocyte markers were altered in all analyzed brain regions except the cortex. The distribution of microglia was modified only in the cortex. The analysis of neuronal markers demonstrated that the architecture of the neuronal layers was affected by cathepsin K deficiency in particular in the hippocampus, a region of the CNS known for its importance in the regulation of anxiety and memory. In line with this notion, we observed the highest specific activity of cathepsin K within this brain region.
Finally, behavioral studies showed that general locomotor function was not obviously affected in Ctsk-/- mice, at least up to the age of 6 months. However, importantly, a clear impact of cathepsin K deficiency on learning and memory as well as novelty seeking was revealed.
Linking brain and thyroid functions of cathepsin K
Previously, we have shown that cathepsin K- and L-double deficient mice are hypothyroid . Hypothyroid conditions in early post-natal stages are considered to negatively affect the development of the CNS . The abnormal state of cerebellar development during this period is one of the most obvious indications for severe hypothyroidism expected to affect adult brain structure and function significantly . However, cerebellar development of Ctsk -/- mice at post-natal day 12 was indistinguishable from that of WT controls inspected at the same age. Moreover, thyroxine levels in the blood of the Ctsk-/- animals analyzed in our previous study and those investigated in this study were not significantly altered in comparison to WT controls. Thus, although we initially hypothesized that the brain phenotype described in this study could be directly attributed to a mild hypothyroidism, we concluded that this hypothesis was supported neither by the status of early post-natal development of Ctsk -/- mice nor by the thyroid hormone levels determined in the brain of these animals (Sîrbulescu, Dauth, Rehders, Saftig, Jordans, Brix, unpublished). Therefore, we addressed other mechanisms through which cathepsin K deficiency could have affected brain development. Because we show herein that cathepsin K is indeed expressed in the mouse brain and exhibits proteolytic activity in particular in the hippocampus, we suggest a more direct effect of cathepsin K deficiency on the mouse CNS development. To unequivocally distinguish between the effects exerted by a lack of cathepsin K expression in either the thyroid or the CNS of mice, organ-specific knock-outs are required and planned for in our future investigations.
Proteolytic network of the cathepsin K-deficient mouse CNS
Another pathway which might lead to the pronounced changes observed in the CNS of Ctsk-/- mice is via modulation of related proteases. Compensatory phenomena underlying the mild phenotypes in mice lacking only one cysteine cathepsin have been previously described to occur in a cell type and tissue specific manner [1, 8]. Interestingly, while cathepsins B and L, which are closely related to cathepsin K, showed altered expression levels in various brain regions, the distantly related aspartic protease cathepsin D was not affected in the brain of Ctsk-/- animals.
Cathepsin B has been associated with neuronal survival by a variety of studies, often with conflicting results. While cathepsin B of microglial origin has been shown to serve as an initiator of apoptosis in cultures of hippocampal  and cortical neurons , its absence has been associated with the death of motor neurons in amyotrophic lateral sclerosis . A cathepsin B-like protease has been implicated in dendritic spine collapse in hippocampal neurons, a process which mediates neuronal synaptic plasticity . A decrease in protein level or activity of this protease, as observed in the cortex and striatum/mesencephalon of Ctsk-/- mice, may therefore carry a multitude of consequences, including an overall enhancement of neuronal activity and/or metabolism. Moreover, the decrease in the activity levels of cathepsin B correlated with a strong increase in the levels of synaptotagmin in the striatum/mesencephalon, suggesting that mechanisms mediating neuronal plasticity may be altered in Ctsk-/- mice.
Cathepsin L, the most similar in structure and function to cathepsin K, showed a significant decrease in protein levels in the cortex of Ctsk-/- mice, while in the hippocampus an increase was observed. Activity, however, was moderately decreased in the striatum/mesencephalon, hippocampus, and cerebellum. A series of studies suggest that cathepsin L is involved in the maturation of the peptide neurotransmitter enkephalin from its proenkephalin precursor . In turn, enkephalin has been shown to interact with the dopaminergic system via D2 receptors .
It is interesting to note that we have observed variations not only in the expression levels of cathepsins B and L, but also in those of cystatin C, an endogenous cathepsin inhibitor with extracellular functions . Cystatin C may act as a safe-guarding inhibitor of cysteine cathepsins after their release from damaged cells under challenging conditions that involve cell death . A recent study described cystatin C as having neuroprotective effects on murine primary cortical neurons and neuronal cell lines, by inducing autophagy and thereby improving clearance of long-lived proteins . Cystatin C is also a well established marker of brain tumours such as gliomas . The significance of cystatin C upregulation in the hippocampus of Ctsk-/- mice, thus, needs to be further investigated.
Cystatin B, another endogenous cysteine cathepsin inhibitor with mainly intracellular safe-guarding tasks, has been shown previously to be required for normal CNS function. Patients with cystatin B mutations suffer from the Unverricht Lundborg syndrome, a disorder associated with epileptic seizures . Because the cathepsin K-deficient mice exhibited striking neurobehavioral phenotypes, although no signs of epilepsy were detectable, it will be important in the future to determine the levels of cysteine cathepsin inhibitors in the CNS of Ctsk-/- mice in more detail. In an elegant approach aiming at the understanding of fine-tuning proteolytic activities at the genome level, mouse models of cystatin B deficiency have been crossed with cathepsin B- and/or L-deficient animals  but not yet with Ctsk-/- mice. From the results of this study and those of Houseweart and colleagues it is, however, clear that altered ratios of cysteine proteases and their inhibitors occur in the brain of cysteine cathepsin and/or cystatin-deficient mice. This is of relevance, considering that certain inherited mutations or an imbalance of cathepsins and their endogenous inhibitors in the brain of both mice and humans have been linked to a number of severe impairments [18, 19, 46].
Changes in cellular architecture resulting from cathepsin K deficiency
In the present work, we observed significantly fewer astrocytes in the hippocampus and significantly more in the cortex of Ctsk-/- mice. Astrocytes have a wide range of functions that are highly relevant for CNS homeostasis and for proper neuronal function [47, 48]. In pathological situations, including neurodegeneration, activation of astrocytes as characterized by an overexpression of GFAP , and astrogliosis, an abnormal increase in the number of astrocytes in damaged areas of the CNS, has been observed . It is therefore not surprising that due to changes in maturation and numbers of astrocytes in Ctsk-/- mice, other cell types like oligodendrocytes and neurons may be affected as well. An enhanced signal of the microglial marker Iba1 was detected in parallel to the increased astrocyte population in the cortex of Ctsk-/- animals. This is interesting to note, because microglia respond to any kind of injury or perturbation of the CNS and it is believed that they play an essential role both in acute neuroinflammation and in wound healing [28, 50]. Therefore, higher levels of cortical Iba1 are in line with the observations of higher GFAP levels in the cortex of Ctsk-/- mice, thereby putatively hinting to an altered composition of neurosupportive, neurotrophic, and repair-promoting factors in some regions of the brain.
Dopaminergic system of Ctsk-/- mice and impact on neurobehavioral tasks
The overall changes observed in the dopaminergic system of Ctsk-/- mice are of particular interest, since dopamine-mediated neuromodulation is involved in a wide variety of processes, including movement and motor learning, novelty seeking, reward processing, fear conditioning, food intake, nociception, and endocrine and autonomic regulation [29, 51, 52]. In addition, the dopaminergic system is known to have an important role in both spatial and non-spatial learning . Ctsk-/- mice in the present study displayed significantly increased levels of tyrosine hydroxylase, the initial and rate-limiting enzyme in dopamine biosynthesis  and slightly increased levels of dopamine. Interestingly, D2-receptor levels were also significantly increased in the striatum/mesencephalon fraction of Ctsk-/- mice. Agonists of D2 receptors, such as RU 24213 or quinpirole have been shown to induce learning impairments  and to decrease anxiety levels in mice , respectively. In line with this notion, in the present study we observed that Ctsk-/- mice displayed reduced anxiety levels and impairments in learning and memory skills while exhibiting enhanced dopamine and increased D2-receptor levels in comparison to WT controls.
Another mechanism by which cathepsin K might affect the dopaminergic system could be via its contribution to opioid metabolism. Up-regulation of cathepsin K expression in rats was directly linked to schizophrenia induced by treatment with neuroleptics . Interestingly, post-mortem brain tissue from patients with schizophrenia also revealed an increase in the cathepsin K protein levels . A recent in vitro study has further shown that cathepsin K can metabolize β-endorphin to produce met-enkephalin . Met-enkephalin binds to opiate receptors, leading to an inhibitory effect on dopaminergic neurons of the VTA . Accordingly, we propose that in the absence of cathepsin K activity, less met-enkephalin would be produced, thus lowering the inhibitory effect on the VTA dopaminergic neurons and leading to increased dopaminergic output.
The deregulated cysteine cathepsin network, the alterations in the cellular architecture of the hippocampus, and the marked metabolic changes observed in Ctsk-/- mice which included the dopaminergic system, prompted us to investigate whether these modifications resulted in altered behavioral patterns. Since both the hippocampus and the dopaminergic system are crucially involved in learning and memory  as well as in anxiety-related behavior , we focused on several tests addressing these aspects.
It is important to mention that, although cathepsin K is well known for its implication in bone remodeling [4, 7, 58], the mice used in this study did not show any sign of physical impairment, likely because they were used at a young age, of up to 6 months. Moreover, a pilot study on a separate group of Ctsk-/- and WT animals (n = 10 for each genotype), using the pole test and the wire hang test, which assess motor abilities in mice , showed no difference between the two groups [Sîrbulescu, Jordans, Lerchl, Saftig, Brix; unpublished observations].
In a series of tests chosen to assess anxiety, exploration and memory [60–62], Ctsk-/- mice showed decreased anxiety and marked spatial and non-spatial learning and memory impairments. Previous studies have linked an overactive dopaminergic system to reduced inhibition in rodents [51, 63]. Our results of the behavioral tests are therefore in line with the observed increase of dopaminergic output in Ctsk-/- mice. Moreover, the neuronal cytoarchitecture of the ventral hippocampus was affected more severely by cathepsin K deficiency than that of the dorsal hippocampus. The ventral hippocampus has been shown to be involved in regulating emotion-related behavior . Lesions applied in this area typically lead to reduced anxiety levels in rodents . In addition, the alterations in astrocyte numbers and maturation states observed in the ventral hippocampus of Ctsk -/- animals may contribute to the observed changes in the distribution and numbers of neurons, which in turn can lead to the observed behavioral phenotypes.
Ctsk -/- mice also showed marked impairments in both non-spatial learning, as indicated by their inability to discriminate the introduction of a novel object into a familiar environment, and in spatial learning tasks, as demonstrated by the multiple choice maze paradigm. These results are in agreement with the profound metabolic disruptions found at the level of both the dopaminergic system and the hippocampus in these animals, because the dopaminergic system is known to have an important role in spatial and non-spatial learning  while the hippocampus is well established as a structure with an essential role for spatial but also for non-spatial memory formation .
Our results suggest that cathepsin K deficiency in mice has a multiple-level impact on brain development and metabolism. To learn more about which cysteine cathepsins may be most crucial in substituting for the decreased cathepsin K activity, it will be important to identify the natural substrates of cathepsin K in the CNS. Another approach could include mice with double deficiencies in cathepsins B and K, or K and L. The use of such double-deficient animals has been instrumental in specifying the thyroid functions of cathepsin K and helped identifying thyroglobulin as one of its natural targets [1, 8, 12, 13, 16].
From this and other recent studies it becomes clear at this point that the activity of cathepsin K has far-reaching effects throughout various organs. This is of highest importance in light of recent advances in the development of targeted cathepsin K inhibitors, aimed at treating osteoporosis [8, 20, 58]. Such compounds are already in late clinical trials and may be used in patients in the near future [7, 34]. In particular, basic cathepsin K inhibitors such as Balicatib and L-006235 have been reported to increase the expression and activity levels of cathepsins B and L in peripheral organs of rats, i.e. liver, kidney, and spleen, but also in the CNS, by factors reaching up to 80-fold . Therefore, clinical trials are now focused on non-basic cathepsin K inhibitors such as Odanacatib, which is currently in phase III clinical trials and expected to be completed in 2012 [34, 58]. It has been pointed out, however, that long-term safety and implications of inhibition of cathepsin K activity are not fully known at this point [7, 8, 58].
Interestingly, pycnodysostosis patients suffering from lifelong absence of cathepsin K activity have been occasionally reported to exhibit, in addition to the abnormalities in bone development, alterations in the CNS such as hyperplasia of the pituitary, demyelination of the cerebrum, and imbalances between brain growth, vascular supply, and cerebrospinal fluid pressure, with complications including sensorineural deafness and frontal porencephalic cysts .
We suggest that Ctsk-/- mice provide a useful tool to better understand the multiple functions that cathepsin K fulfils in the CNS, in addition to its well-established roles in peripheral tissues. Considering the above-mentioned observations in mice, rats, and humans, it will be worthwhile to address off-target effects of cathepsin K inhibitors on the CNS of patients, since a dopaminergic induction similar to the one observed in this study could help in the treatment of neurodegenerative disorders, such as Parkinson's disease, in addition to managing the symptoms of osteoporosis.
All studies were performed on 12-26 weeks-old male Ctsk-/- or WT C57Bl/6J mice. The mice were back-crossed to a congenic C57Bl/6J background in the animal facility of Jacobs University Bremen, Germany. Back-crossing was performed over 6 generations for mice used in the investigations of the brain cytoarchitecture, and in the studies of metabolic markers. Mice back-crossed over 8 to 11 generations were used for PCR, cathepsin immunofluorescence and activity studies. Generation of the founder Ctsk-/- mice at University of Göttingen, Germany, and the genotyping methods are described elsewhere . For the experiments, mice were singly housed under standard conditions, with a 12 h/12 h light/dark cycle with lights out at 07:00 p.m. and ad libitum water and food. Testing was conducted in accordance with institutional guidelines, in S1-laboratories of Jacobs University Bremen (SfAFGJS Az. 513-30-00/2-15-32 and 522-27-11/3-1, 05-A20 and A21).
Activity frequency recordings
Analysis of diurnal variations in locomotor activity was performed as described  using 4-6 months old, male Ctsk-/- mice and WT controls (n = 5 per genotype). Each mouse was singly-housed over a time period of four weeks, and the activity patterns were determined for the last three weeks. Movements were measured via passive infrared sensor detectors (PIDs; 35 × 29.5 × 20 mm; L × W × H) (Conrad Electronic SE, Hirschau, Germany) which were installed with a coverage angle of 100° about 13 cm above each cage. A QuickBasic program was written for the registration of locomotor activity by PIDs (by courtesy of Dr. Steinlechner, Tierärztliche Hochschule Hannover, Germany) checking all PID channels and the channel for the light sensor.
Behavioral tests were carried out during the light phase, between 2 and 5 p.m. The order of testing for the two genotypes was routinely alternated in order to reduce effects of diurnal rhythm. Behavioral tests were videotaped using a webcam positioned directly above the testing area and visualized on a computer screen. Behavior was coded directly, using Ethograph 2.06 software (Ritec, St. Petersburg, Russia).
Elevated plus maze
The plus-shaped maze was constructed from opaque white Plexiglas®, with 4 arms of equal length (50 cm) and width (5 cm) extending from a central square platform (side: 5 cm). Closed arms were bordered by side walls (height: 20 cm), while the two open arms did not have any lateral boundaries. The maze was elevated on poles 50 cm above ground. Each mouse was placed on the central platform, facing the same closed arm, and allowed to explore the maze for a single trial lasting 5 min, after which it was returned to its home cage. The time spent in closed or open arms as well as on the central platform was recorded for each individual.
Hole board test
A square wooden box of 60 × 60 × 35 cm was used for testing. The inside of the box was painted black, and the floor was divided into nine equal squares. Four holes with a diameter of 3.5 cm were located at the corners of the central square. The floor was elevated 10 cm above the bottom of the box. Individual animals were placed in the lower left corner of the enclosure, facing the wall, and allowed to explore freely for 3 min, after which the mice were returned to the home cage. The number of head dips into holes, rearings, and squares crossed were recorded as described above, the latter serving as a general index of locomotor activity. The number of center crossings was recorded and considered as an indirect measure of anxiety.
Novel object recognition test
A box similar to the one described above was used, however lacking the floor holes. Four different objects were placed in squares 1, 4, 6 and 8 during the test: a wooden cube (side: 3.5 cm), a plastic Lego® corner (side: 2 cm, height: 1.5 cm), a plastic Lego® house shape (length: 4 cm, width: 2 cm, height: 3 cm) and a gyps ellipsoid (long radius: 5 cm; short radii: 3.5 cm). Additionally, for the object substitution test, a shell (length: 5 cm, width: 2.5 cm, height: 2 cm) was used as a novel object. Mice were placed in the testing arena, as described above. During the first day of testing, the animals were given two consecutive 3-min habituation sessions, with an inter-session interval of one hour. On the next day, one of the objects (cube) was replaced with an unfamiliar one (shell). Mice were again allowed to explore the setting for 3 min. The total time spent in each of the squares containing an object was determined.
Elevated multiple-choice maze
The maze was constructed out of opaque white Plexiglas® strips, with a width of 5 cm and a total length of 265 cm, elevated on poles with a height of 50 cm. Animals were placed in the starting segment of the maze, and had to make three correct decisions in order to reach the exit point. There they could descend via a wire net into a cage containing a house, which was placed on the floor and was not readily visible from the maze. The maximum duration of one trial was 3 min. Testing was conducted daily, over an interval of 12 days. An entry into a maze segment that was outside the correct route (0-1-4-7-E-F in this order, see Figure 8C) was counted as a reference memory error, while backtracking into any already visited segment within a given session was counted as a working memory error.
Mice were anesthetized, the abdominal and thoracic cavities were opened and the abdominal aorta was cut. Perfusion was carried out through the heart with 0.9% NaCl supplemented with 200 IU heparin (Braun Melsungen AG, Melsungen, Germany). The head and neck regions were immediately separated and placed on ice.
The brain was removed and the two hemispheres were separated. One hemisphere was placed in 4% PFA in 200 mM HEPES, pH 7.4, and left overnight at 4°C, then cryo-preservation was carried out by incubating in 0.5 M and afterwards in 1 M sucrose solution in phosphate-buffered saline (PBS), pH 7.4, for each another 24 h at 4°C. Tissue samples were embedded in Tissue Freezing Medium (Jung, through Leica Microsystems) and stored at -20°C. Alternatively, tissue was frozen using the liquid nitrogen-isopentane method and stored at -80°C until sectioning. The other hemisphere was immediately dissected on ice and the cortex, hippocampus, cerebellum, and striatum together with the mesencephalon and diencephalon (referred to as striatum/mesencephalon fraction) were separated and snap-frozen in liquid nitrogen.
SDS-PAGE, immunoblotting, immunodetection and densitometry
Tissue samples were homogenized in ice-cold PBS containing 0.5% Triton X-100, using a Potter S homogenizer (Sartorius, Göttingen, Germany) at 1,000 rpm for 5 min. Further extraction was performed by placing the resulting homogenates in a rotary mixer for 40 min at 4°C. After centrifugation at 10,000 ×-g and 4°C for 10 min, the supernatants were removed and stored at -20°C.
The protein content of all samples was determined using the Neuhoff assay . Tissue lysates were normalized to equal amounts of protein, boiled in sample buffer and separated on 12.5% acrylamide gels.
Immunoblotting and immunodetection
Separated proteins were semi-dry blotted onto nitrocellulose membrane. Blocking was done overnight at 4°C using 5% milk powder in PBS containing 0.3% Tween-20 (PBST). Primary antibodies, sheep anti-tyrosine hydroxylase (AB1542, Chemicon, Billerica, MA, USA), rabbit anti-dopamine D2 receptor (ab21218, Abcam, Cambridge, UK), mouse anti-GFAP (G3893; Sigma-Aldrich Chemie GmbH, Taufkirchen, Germany), mouse anti-CNPase (C5922; Sigma), chicken anti-synaptotagmin (AB9356; Chemicon), rabbit anti-cystatin C (9300; kind gift of Dr. Magnus Abrahamson, Lund, Sweden), goat anti-mouse cathepsin B (GT15047, Neuromics, through Acris Antibodies, Herford, Germany), rabbit anti-human cathepsin D (IM16, Calbiochem-Novabiochem GmbH, Bad Soden, Germany), and goat anti-mouse cathepsin L (GT15049, Neuromics) were applied for 1.5 h at room temperature. The appropriate secondary antibodies, either HRP-conjugated donkey anti-sheep IgG (713-035-003, Immunoresearch Europe Ltd., Suffolk, UK), goat anti-rabbit IgG (4050-05, Southern Biotech, Birmingham, Alabama, USA), rabbit anti-goat IgG (6160-05; Southern Biotech),or goat anti-chicken IgG (6100-05; Southern Biotech) were applied for 1 h at room temperature. As a loading control, membranes were stripped and re-probed for either glyceraldehyde 3-phosphate dehydrogenase (GAPDH), using a rabbit anti-GAPDH primary antibody (ab9485, Abcam), or for β-tubulin, using a rabbit anti-β-tubulin primary antibody (T-3526, Sigma), and an HRP-conjugated goat anti-rabbit secondary antibody, as described above. Immunoreactions were visualized by enhanced chemiluminescence on CL-XPosure film (Pierce through Perbio Science Europe, Bonn, Germany) or on Hyperfilm MP (GE Healthcare Europe GmbH, Munich, Germany).
Films from two to seven different blots for each immunodetection and each animal were scanned with a transmitted-light scanner (Desk Scan II version 2.9; Hewlett-Packard Co., Palo Alto, California, USA) and evaluated densitometrically using TINA version 2.09d (Raytest Isotopen-Messgeräte GmbH, Straubenhardt, Germany). The measured optical density/mm2 values, after background subtraction, were normalized within each blot by dividing individual values to the average of the WT mice values in the respective blot. For normalization β-tubulin was used. For averaging over different immunoblot intensities varying from membrane to membrane values are given as percent of control, e.g. the average of the WT values were set to 100% and each single value (WT and Ctsk-/-) was then compared to this average value. For quantification of cathepsin protein levels (see, Additional file 1) the bands representing the mature forms, i.e. single chain, or heavy and light chains of two-chain-forms of the respective cathepsins were analyzed by densitometry (see also, Additional file 2).
Brain tissue from WT (cortex, striatum/mesencephalon, hippocampus and cerebellum) and Ctsk-/- (cortex) mice was homogenized in PBS containing 0.5% Triton X-100 as described above. After centrifugation at 12,000 rpm, pellets were collected and used for RNA extraction using Trizol (Invitrogen), chloroform and isopropanol as described in . RNA concentration was determined by NanoDrop™ (Kiesker, Steinfurt, Germany). Reverse transcription was performed using 2U reverse transcriptase (Quiagen, Hilden, Germany) and 1 μg RNA according to the manufacturer's instructions. The following primers were used for amplification: Cathepsin K 5'-GCC AGG ATG AAA GTT GTA TG-3' (forward), 5'-CAG GCG TTG TTC TTA TTC C-3' (reverse); β-actin: 5'-GCC AGG ATG AAA GTT GTA TG-3' (forward), 5'-CAG GCG TTG TTC TTA TTC C-3' (reverse). Cathepsin K cDNA was amplified by an initial denaturation of 1 min at 95°C, followed by 35 cycles, each consisting of 1 min at 95°C (denaturation), 1 min at 53.4°C (annealing), and 1 min at 72°C (elongation). The amplification of β-actin cDNA consisted of 26 repeats of 30-sec cycles of denaturation at 95°C, annealing for 20 sec at 58°C and elongation for 45 sec at 72°C. The reactions were terminated through incubation for 7 min at 72°C.
For determining levels of dopamine, commercially available ELISA kits were used. Tissue extracts from fractions including the dopaminergic system were first acidified by adding HCl to a final concentration of 0.01 N and then used in a dopamine enzyme immunoassay (Dopamine Research EIA, KAPL10-5300, BioSource Europe S.A., Nivelles, Belgium) according to the manufacturer's manual.
Cathepsin activity assays
The enzyme activity assay was performed as described in  and with variations as detailed in  by monitoring cleavage of 5 μM cathepsin B substrate N-benzyloxycarbonyl-arginyl-arginine-7-amido-4-methylcoumarin (Z-Arg-Arg-AMC; Bachem Distribution Services GmbH, Weil am Rhein, Germany) at pH 6.0 for 10 min at 40°C, 1.5 μM CA-074 cathepsin B-specific inhibitor (Merck Biosciences GmbH, Darmstadt, Germany) plus 5 μM cathepsin L substrate N-benzyloxycarbonyl-phenylalanyl-arginine-7-amido-4-methylcoumarin (Z-Phe-Arg-AMC; Bachem Distribution Services GmbH) at pH 5.5 for 10 min at 30°C, and 5.6 μM cathepsin K substrate ο-aminobenzoic acid-histidyl-prolyl-glycyl-glycyl-prolyl-glutaminyl- N-(2,4-dinitrophenyl)-ethylene diamine (Abz-HPGGPQ-EDN2ph) [12, 24] at pH 5.5 for 10 min at 30°C. Negative controls were run in parallel with the addition of 10 μM of the cysteine protease inhibitor E64. Reactions were terminated by adding stop solutions and fluorescence was measured with a Tecan GENios Reader (Tecan Deutschland GmbH, Crailsheim, Germany), using an excitation wavelength of 360 nm and reading the emission at 465 nm for cathepsin B and L activity assays, whereas cathepsin K activity was determined with an excitation at 320 nm and emission set to 420 nm.
Activity was tested as previously described  with variations as detailed in  by monitoring cleavage of cathepsin D substrate 7-methoxycoumarin-4-yl-acetyl-glycyl-lysyl-prolyl-isoleucyl-phenylalanyl-phenylalanyl-arginyl-leucyl-lysine (2, 4-dinitrophenyl)-D-arginine (MOCAc-Gly-Lys-Pro-Ile-Leu-Phe ~ Phe-Arg-Leu-Lys (Dnp)-D-Arg-NH2; Merck Biosciences GmbH) at pH 4.0 for 10 min at 40°C. Controls were incubated in addition with 1 μM pepstatin A (Sigma-Aldrich Chemie GmbH, Taufkirchen, Germany). Reactions were stopped and fluorescence was measured using an excitation wavelength of 328 nm and reading the emission at 393 nm.
All assays were performed in duplicates and repeated 2-4 times. For each genotype, three to six different mice were used, except for cathepsin B and L striatum/mesencephalon, where eight mice were used. Relative fluorescence units (RFU) of controls were subtracted from the values of the corresponding samples. In order to allow averaging over several assays, RFU values were normalized by the averages of the WT measurements within a given assay. For calculation of specific cathepsin K activity, RFU values were divided by protein contents of the respective samples.
Immuno- and enzyme histochemistry
Brain hemispheres were cut horizontally on a cryostat (Leica CM1900, Leica Microsystems) into 16 μm sections and thaw-mounted serially on microscope slides. Residual embedding material was washed out prior to the staining procedure by incubating slides overnight in PBS at 4°C. Blocking of non-specific binding sites on sections was performed at room temperature by a 4 h- or 1.5 h-incubation with 3% bovine serum albumin (Albumin Fraction V, Roth, Karlsruhe, Germany) including 0.3% or 0.1% Triton X-100 in calcium and magnesium-free PBS (CMF-PBS), respectively. Primary antibodies, mouse anti-tyrosine hydroxylase (MAB318, Chemicon), mouse anti-GFAP (G3893; Sigma), mouse anti-Neuronal Nuclei (NeuN) (MAB377, Millipore, CA, USA), mouse anti-human cathepsin K (IM55, Calbiochem-Novabiochem GmbH), and rabbit anti-Iba1 (016-20001; Wako Pure Chemical Industries, Japan) antibodies were applied overnight at 4°C. Secondary antibodies, goat anti-mouse IgG conjugated with Alexa 546 (A11018, Invitrogen through Molecular Probes, Karlsruhe, Germany) or Alexa 488 (A11017, Invitrogen), and goat anti-rabbit IgG conjugated with Alexa 488 (A11034, Invitrogen) were applied for 4 h on brain sections at room temperature in a moisturized chamber.
Cathepsin K activity assays by enzyme histochemistry
Cryo-sections of 0.5% PFA fixed brain tissue were washed several times in PBS to remove embedding medium before pre-incubation for 5 min at 37°C in reducing reaction buffer consisting of 0.2 M ammonium acetate, 0.125 mM β-mercaptoethanol, 0.1 mM EDTA-Na2, 0.5 M Na2HPO4, pH 6.2, and subsequent incubation under oxygen-free conditions in reaction buffer supplemented with 1 mM cathepsin K substrate Z-glycinyl-prolyl-arginyl-4-methoxy-β-naphthylamine (Z-Gly-Pro-Arg-4MβNA; J1105, Bachem) for 45 min in the presence of 1 mM nitrosalicyl aldehyde (NSA) as the precipitating agent of released 4MβNA as previously described . Thereafter, sections were washed and mounted in PBS, and the insoluble precipitates were visualized at an excitation of 435 - 490 and the emission set to 520 - 530 nm by META-detection with the LSM 510 (see below).
Microscopy and analysis
Confocal images were taken using a Zeiss LSM 510 META laser-scanning microscope equipped with Argon and Helium-Neon lasers (Carl Zeiss GmbH, Oberkochen, Germany). Optical sections were taken with a pinhole opening of 1 Airy unit and at a resolution of 1,024 × 1,024 pixels, using LSM 5 software (version 3.2; Carl Zeiss).
Analysis of hippocampus sections
A total of 278 horizontal sections from the ventral hippocampus and 582 horizontal sections of the dorsal hippocampus were immunolabeled for NeuN and analyzed. For each genotype, six different mice were used. Confocal images taken from the DG, CA1, CA2, and CA3 regions were analyzed using CellProfiler 2.0, version 9777 . The image processing and analysis command pipelines were run under MATLAB (The MathWorks, Inc., Natick, MA). Briefly, images were exported as greyscale pictures and neuronal nuclei were identified according to intensity by application of thresholding and smoothing filters. The number of nuclei per image and the number of nearest neighbours within a 15-pixel (~7 μm) distance of any given nucleus were determined. In order to take into account that neuronal numbers may differ, special care was taken in order to analyze comparable numbers of neurons.
Normal distribution of all data sets was verified using the Kolmogorov-Smirnov test. Two-tailed Student's t-test was used to assess group differences for data from the elevated plus maze, hole board test, immunoblot densitometry, ELISA and morphometric analyses. For analyzing data from the novel object recognition test and elevated multiple choice maze, repeated measures analysis of variance (ANOVA) was used, with significance levels for multiple comparisons corrected using the Bonferroni procedure. For assessing differences in the neuronal distributions the Kolmogorov-Smirnov and the Mann-Whitney U test were used. All data are shown as mean ± standard error of the mean, except for Figure 2 and Additional file 3, which show mean ± standard deviation.
List of abbreviations
- Abz-HPGGPQ-EDN2pH - ο-aminobenzoic acid-histidyl-prolyl-glycyl-glycyl-prolyl-glutaminyl-N-(2:
central nervous system
- Ctsd -/- :
cathepsin D deficient
- Ctsk -/- :
cathepsin K deficient
dopamine type 2 receptors
enzyme linked immunosorbent assay
glial fibrillaric acidic protein
ionized calcium binding adapter protein 1
passive infrared sensor detectors
reverse transcriptase - polymerase chain reaction
- Str or:
striatum/mesenceph. - striatum/mesencephalon
ventral tegmental area
The authors are indebted to Thomas Ströhlein for professional help in the transgenic animal facility at Jacobs University, and to Iulian Ilieş for helpful advice concerning data analysis. The contributions of Anna Huber, Meike Klepsch, Ruxandra Mutihac, and Arian Aryani Kashani (all, then, Jacobs University) during the initial phase of this project are gratefully acknowledged. The authors are grateful to Dr. Nicole M. Kühl (then, Jacobs University) for helpful advice and suggestions during the starting phase of this project. We would like to thank Dr. Magnus Abrahamson (University of Lund, Sweden) for the kind gift of anti-cystatin C antibodies, and Prof. Dr. Stephan Steinlechner (Tierärztliche Hochschule Hannover, Germany) for the QuickBasic program used for registration of locomotor activity.
The study was supported by Jacobs University Bremen 2140/90033 and 2140/90140 to KBr; SD, RFS and SJ received stipends from the School of Engineering and Science, Jacobs University Bremen, enabling Graduate- and PhD-studies.
- Brix K, Dunkhorst A, Mayer K, Jordans S: Cysteine cathepsins: cellular roadmap to different functions. Biochimie. 2008, 90: 194-207. 10.1016/j.biochi.2007.07.024.View ArticlePubMed
- Bromme D, Okamoto K: Human cathepsin O2, a novel cysteine protease highly expressed in osteoclastomas and ovary molecular cloning, sequencing and tissue distribution. Biol Chem Hoppe Seyler. 1995, 376: 379-384. 10.1515/bchm3.1995.376.6.379.View ArticlePubMed
- Gelb BD, Shi GP, Chapman HA, Desnick RJ: Pycnodysostosis, a lysosomal disease caused by cathepsin K deficiency. Science. 1996, 273: 1236-1238. 10.1126/science.273.5279.1236.View ArticlePubMed
- Saftig P, Hunziker E, Wehmeyer O, Jones S, Boyde A, Rommerskirch W, Moritz JD, Schu P, von Figura K: Impaired osteoclastic bone resorption leads to osteopetrosis in cathepsin-K-deficient mice. Proc Natl Acad Sci USA. 1998, 95: 13453-13458. 10.1073/pnas.95.23.13453.PubMed CentralView ArticlePubMed
- Kiviranta R, Morko J, Uusitalo H, Aro HT, Vuorio E, Rantakokko J: Accelerated turnover of metaphyseal trabecular bone in mice overexpressing cathepsin K. J Bone Miner Res. 2001, 16: 1444-1452. 10.1359/jbmr.2001.16.8.1444.View ArticlePubMed
- Desmarais S, Masse F, Percival MD: Pharmacological inhibitors to identify roles of cathepsin K in cell-based studies: a comparison of available tools. Biol Chem. 2009, 390: 941-948. 10.1515/BC.2009.092.View ArticlePubMed
- Podgorski I: Future of anticathepsin K drugs: dual therapy for skeletal disease and atherosclerosis?. Future Med Chem. 2009, 1: 21-34. 10.4155/fmc.09.4.PubMed CentralView ArticlePubMed
- Dauth S, Arampatzidou M, Rehders M, Yu DMT, Führer D, Brix K: Thyroid cathepsin K - roles in physiology and thyroid disease. Clin Rev Bone and Miner Metab. 2011, 9: 94-106. 10.1007/s12018-011-9093-7.View Article
- Punturieri A, Filippov S, Allen E, Caras I, Murray R, Reddy V, Weiss SJ: Regulation of elastinolytic cysteine proteinase activity in normal and cathepsin K-deficient human macrophages. J Exp Med. 2000, 192: 789-799. 10.1084/jem.192.6.789.PubMed CentralView ArticlePubMed
- Buhling F, Gerber A, Hackel C, Kruger S, Kohnlein T, Bromme D, Reinhold D, Ansorge S, Welte T: Expression of cathepsin K in lung epithelial cells. Am J Respir Cell Mol Biol. 1999, 20: 612-619.View ArticlePubMed
- Haeckel C, Krueger S, Buehling F, Broemme D, Franke K, Schuetze A, Roese I, Roessner A: Expression of cathepsin K in the human embryo and fetus. Dev Dyn. 1999, 216: 89-95. 10.1002/(SICI)1097-0177(199910)216:2<89::AID-DVDY1>3.0.CO;2-9.View ArticlePubMed
- Tepel C, Bromme D, Herzog V, Brix K: Cathepsin K in thyroid epithelial cells: sequence, localization and possible function in extracellular proteolysis of thyroglobulin. J Cell Sci. 2000, 113: 4487-4498.PubMed
- Jordans S, Jenko-Kokalj S, Kuhl NM, Tedelind S, Sendt W, Bromme D, Turk D, Brix K: Monitoring compartment-specific substrate cleavage by cathepsins B, K, L, and S at physiological pH and redox conditions. BMC Biochem. 2009, 10: 23-10.1186/1471-2091-10-23.PubMed CentralView ArticlePubMed
- Bernstein HG, Bukowska A, Dobrowolny H, Bogerts B, Lendeckel U: Cathepsin K and schizophrenia. Synapse. 2007, 61: 252-253. 10.1002/syn.20358.View ArticlePubMed
- Sîrbulescu R, Jordans S, Lerchl A, Saftig P, Kühl NM, Brix K: Trafficking of cysteine cathepsin to the extracellular thyroid follicle lumen helps mice to improve their memory and learning skills. In Book of abstracts/Xth International Symposium on Proteinase Inhibitors and Biological Control, Portoroz, Slovenia, June 23-27, 2007. Edited by: Dolinar M, Stoka V, Turk B and Turk V. 2007, Jožef Stefan Institute, Ljubljana, Slovenia, 53.
- Friedrichs B, Tepel C, Reinheckel T, Deussing J, von Figura K, Herzog V, Peters C, Saftig P, Brix K: Thyroid functions of mouse cathepsins B, K, and L. J Clin Invest. 2003, 111: 1733-1745.PubMed CentralView ArticlePubMed
- Koike M, Nakanishi H, Saftig P, Ezaki J, Isahara K, Ohsawa Y, Schulz-Schaeffer W, Watanabe T, Waguri S, Kametaka S, Shibata M, Yamamoto K, Kominami E, Peters C, von Figura K, Uchiyama Y: Cathepsin D deficiency induces lysosomal storage with ceroid lipofuscin in mouse CNS neurons. J Neurosci. 2000, 20: 6898-6906.PubMed
- Felbor U, Kessler B, Mothes W, Goebel HH, Ploegh HL, Bronson RT, Olsen BR: Neuronal loss and brain atrophy in mice lacking cathepsins B and L. Proc Natl Acad Sci USA. 2002, 99: 7883-7888. 10.1073/pnas.112632299.PubMed CentralView ArticlePubMed
- Houseweart MK, Pennacchio LA, Vilaythong A, Peters C, Noebels JL, Myers RM: Cathepsin B but not cathepsins L or S contributes to the pathogenesis of Unverricht-Lundborg progressive myoclonus epilepsy (EPM1). J Neurobiol. 2003, 56: 315-327. 10.1002/neu.10253.View ArticlePubMed
- Desmarais S, Black WC, Oballa R, Lamontagne S, Riendeau D, Tawa P, Duong le T, Pickarski M, Percival MD: Effect of cathepsin K inhibitor basicity on in vivo off-target activities. Mol Pharmacol. 2008, 73: 147-156.View ArticlePubMed
- Feher LZ, Kalman J, Puskas LG, Gyulveszi G, Kitajka K, Penke B, Palotas M, Samarova EI, Molnar J, Zvara A, Matin K, Bodi N, Hugyecz M, Pakaski M, Bjelik A, Juhasz A, Bogats G, Janka Z, Palotas A: Impact of haloperidol and risperidone on gene expression profile in the rat cortex. Neurochem Int. 2005, 47: 271-280. 10.1016/j.neuint.2005.04.020.View ArticlePubMed
- Ko F, Tallerico T, Seeman P: Antipsychotic pathway genes with expression altered in opposite direction by antipsychotics and amphetamine. Synapse. 2006, 60: 141-151. 10.1002/syn.20287.View ArticlePubMed
- Lendeckel U, Kahne T, Ten Have S, Bukowska A, Wolke C, Bogerts B, Keilhoff G, Bernstein HG: Cathepsin K generates enkephalin from beta-endorphin: a new mechanism with possible relevance for schizophrenia. Neurochem Int. 2009, 54: 410-417. 10.1016/j.neuint.2009.01.011.View ArticlePubMed
- Lecaille F, Weidauer E, Juliano MA, Bromme D, Lalmanach G: Probing cathepsin K activity with a selective substrate spanning its active site. Biochem J. 2003, 375: 307-312. 10.1042/BJ20030468.PubMed CentralView ArticlePubMed
- Kingham PJ, Pocock JM: Microglial secreted cathepsin B induces neuronal apoptosis. J Neurochem. 2001, 76: 1475-1484. 10.1046/j.1471-4159.2001.00146.x.View ArticlePubMed
- Holscher C: Time, space and hippocampal functions. Rev Neurosci. 2003, 14: 253-284. 10.1515/REVNEURO.2003.14.3.253.PubMed
- Asagiri M, Hirai T, Kunigami T, Kamano S, Gober HJ, Okamoto K, Nishikawa K, Latz E, Golenbock DT, Aoki K, Ohya K, Imai Y, Morishita Y, Miyazono K, Kato S, Saftig P, Takayanagi H: Cathepsin K-dependent toll-like receptor 9 signaling revealed in experimental arthritis. Science. 2008, 319: 624-627. 10.1126/science.1150110.View ArticlePubMed
- Streit WJ, Xue QS: Life and death of microglia. J Neuroimmune Pharmacol. 2009, 4: 371-379. 10.1007/s11481-009-9163-5.View ArticlePubMed
- Vaccari A, Rossetti ZL, de Montis G, Stefanini E, Martino E, Gessa GL: Neonatal hypothyroidism induces striatal dopaminergic dysfunction. Neuroscience. 1990, 35: 699-706. 10.1016/0306-4522(90)90340-A.View ArticlePubMed
- Kandel ER: The biology of memory: a forty-year perspective. J Neurosci. 2009, 29: 12748-12756. 10.1523/JNEUROSCI.3958-09.2009.View ArticlePubMed
- Bjorklund A, Dunnett SB: Dopamine neuron systems in the brain: an update. Trends Neurosci. 2007, 30: 194-202. 10.1016/j.tins.2007.03.006.View ArticlePubMed
- Rose AA, Siegel PM: Emerging therapeutic targets in breast cancer bone metastasis. Future Oncol. 2010, 6: 55-74. 10.2217/fon.09.138.View ArticlePubMed
- Yang M, Sun J, Zhang T, Liu J, Zhang J, Shi MA, Darakhshan F, Guerre-Millo M, Clement K, Gelb BD, Dolgnov G, Shi GP: Deficiency and inhibition of cathepsin K reduce body weight gain and increase glucose metabolism in mice. Arterioscler Thromb Vasc Biol. 2008, 28: 2202-2208. 10.1161/ATVBAHA.108.172320.PubMed CentralView ArticlePubMed
- Rachner TD, Khosla S, Hofbauer LC: Osteoporosis: now and the future. Lancet. 2011, 377: 1276-1287. 10.1016/S0140-6736(10)62349-5.PubMed CentralView ArticlePubMed
- Horn S, Heuer H: Thyroid hormone action during brain development: more questions than answers. Mol Cell Endocrinol. 2010, 315: 19-26. 10.1016/j.mce.2009.09.008.View ArticlePubMed
- Portella AC, Carvalho F, Faustino L, Wondisford FE, Ortiga-Carvalho TM, Gomes FC: Thyroid hormone receptor beta mutation causes severe impairment of cerebellar development. Mol Cell Neurosci. 2010, 44: 68-77. 10.1016/j.mcn.2010.02.004.View ArticlePubMed
- Gan L, Ye S, Chu A, Anton K, Yi S, Vincent VA, von Schack D, Chin D, Murray J, Lohr S, Patthy L, Gonzalez-Zulueta M, Nikolich K, Urfer R: Identification of cathepsin B as a mediator of neuronal death induced by Abeta-activated microglial cells using a functional genomics approach. J Biol Chem. 2004, 279: 5565-5572.View ArticlePubMed
- Kikuchi H, Yamada T, Furuya H, Doh-ura K, Ohyagi Y, Iwaki T, Kira J: Involvement of cathepsin B in the motor neuron degeneration of amyotrophic lateral sclerosis. Acta Neuropathol. 2003, 105: 462-468.PubMed
- Graber S, Maiti S, Halpain S: Cathepsin B-like proteolysis and MARCKS degradation in sub-lethal NMDA-induced collapse of dendritic spines. Neuropharmacology. 2004, 47: 706-713. 10.1016/j.neuropharm.2004.08.004.View ArticlePubMed
- Hook V, Yasothornsrikul S, Greenbaum D, Medzihradszky KF, Troutner K, Toneff T, Bundey R, Logrinova A, Reinheckel T, Peters C, Bogyo M: Cathepsin L and Arg/Lys aminopeptidase: a distinct prohormone processing pathway for the biosynthesis of peptide neurotransmitters and hormones. Biol Chem. 2004, 385: 473-480. 10.1515/BC.2004.055.View ArticlePubMed
- Hayward MD, Low MJ: Naloxone's suppression of spontaneous and food-conditioned locomotor activity is diminished in mice lacking either the dopamine D(2) receptor or enkephalin. Brain Res Mol Brain Res. 2005, 140: 91-98.View ArticlePubMed
- Abrahamson M, Alvarez-Fernandez M, Nathanson CM: Cystatins. Biochem Soc Symp. 2003, 179-199.
- Salvesen G, Nagase H: Inhibition of proteolytic enzymes. In Proteolytic Enzymes: a Practical Approach. Edited by: Beyon RJ and Bond JS. 1989, IRL Press at Oxford University, 1983-1104.
- Tizon B, Sahoo S, Yu H, Gauthier S, Kumar AR, Mohan P, Figliola M, Pawlik M, Grubb A, Uchiyama Y, Bandyopadhyay U, Cuervo AM, Nixon RA, Levy E: Induction of autophagy by cystatin C: a mechanism that protects murine primary cortical neurons and neuronal cell lines. PLoS One. 2010, 5: e9819-10.1371/journal.pone.0009819.PubMed CentralView ArticlePubMed
- Nakabayashi H, Hara M, Shimuzu K: Clinicopathologic significance of cystatin C expression in gliomas. Hum Pathol. 2005, 36: 1008-1015. 10.1016/j.humpath.2005.06.021.View ArticlePubMed
- Pennacchio LA, Bouley DM, Higgins KM, Scott MP, Noebels JL, Myers RM: Progressive ataxia, myoclonic epilepsy and cerebellar apoptosis in cystatin B-deficient mice. Nat Genet. 1998, 20: 251-258. 10.1038/3059.View ArticlePubMed
- Barres BA: The mystery and magic of glia: a perspective on their roles in health and disease. Neuron. 2008, 60: 430-440. 10.1016/j.neuron.2008.10.013.View ArticlePubMed
- Fellin T: Communication between neurons and astrocytes: relevance to the modulation of synaptic and network activity. J Neurochem. 2009, 108: 533-544. 10.1111/j.1471-4159.2008.05830.x.View ArticlePubMed
- Rossi D, Volterra A: Astrocytic dysfunction: insights on the role in neurodegeneration. Brain Res Bull. 2009, 80: 224-232. 10.1016/j.brainresbull.2009.07.012.View ArticlePubMed
- Streit WJ: Microglia as neuroprotective, immunocompetent cells of the CNS. Glia. 2002, 40: 133-139. 10.1002/glia.10154.View ArticlePubMed
- Voon V, Fernagut PO, Wickens J, Baunez C, Rodriguez M, Pavon N, Juncos JL, Obeso JA, Bezard E: Chronic dopaminergic stimulation in Parkinson's disease: from dyskinesias to impulse control disorders. Lancet Neurol. 2009, 8: 1140-1149. 10.1016/S1474-4422(09)70287-X.View ArticlePubMed
- Pezze MA, Feldon J: Mesolimbic dopaminergic pathways in fear conditioning. Prog Neurobiol. 2004, 74: 301-320. 10.1016/j.pneurobio.2004.09.004.View ArticlePubMed
- Adriani W, Sargolini F, Coccurello R, Oliverio A, Mele A: Role of dopaminergic system in reactivity to spatial and non-spatial changes in mice. Psychopharmacology (Berl). 2000, 150: 67-76. 10.1007/s002130000423.View Article
- Nagatsu T, Levitt M, Udenfriend S: Tyrosine Hydroxylase. the Initial Step in Norepinephrine Biosynthesis. J Biol Chem. 1964, 239: 2910-2917.PubMed
- Ichihara K, Nabeshima T, Kameyama T: Effects of dopamine receptor agonists on passive avoidance learning in mice: interaction of dopamine D1 and D2 receptors. Eur J Pharmacol. 1992, 213: 243-249. 10.1016/0014-2999(92)90688-Z.View ArticlePubMed
- de Oliveira AR, Reimer AE, Brandao ML: Dopamine D2 receptor mechanisms in the expression of conditioned fear. Pharmacol Biochem Behav. 2006, 84: 102-111. 10.1016/j.pbb.2006.04.012.View ArticlePubMed
- Margolis EB, Lock H, Chefer VI, Shippenberg TS, Hjelmstad GO, Fields HL: Kappa opioids selectively control dopaminergic neurons projecting to the prefrontal cortex. Proc Natl Acad Sci USA. 2006, 103: 2938-2942. 10.1073/pnas.0511159103.PubMed CentralView ArticlePubMed
- Canalis E: New Treatment Modalities in Osteoporosis. Endocr Pract. 2010, 16: 855-863. 10.4158/EP10048.RA.PubMed CentralView ArticlePubMed
- Karl T, Pabst R, von Horsten S: Behavioral phenotyping of mice in pharmacological and toxicological research. Exp Toxicol Pathol. 2003, 55: 69-83. 10.1078/0940-2993-00301.View ArticlePubMed
- Rodriguiz RM, Wetsel WC: Assessments of Cognitive Deficits in Mutant Mice. Animal Models of Cognitive Impairment. Edited by: Levin ED and Buccafusco JJ. 2006, Boca Raton (FL): CRC Press, Chapter 12
- Pellow S, Chopin P, File SE, Briley M: Validation of open:closed arm entries in an elevated plus-maze as a measure of anxiety in the rat. J Neurosci Methods. 1985, 14: 149-167. 10.1016/0165-0270(85)90031-7.View ArticlePubMed
- Karasawa J, Hashimoto K, Chaki S: D-Serine and a glycine transporter inhibitor improve MK-801-induced cognitive deficits in a novel object recognition test in rats. Behav Brain Res. 2008, 186: 78-83. 10.1016/j.bbr.2007.07.033.View ArticlePubMed
- Zhuang X, Oosting RS, Jones SR, Gainetdinov RR, Miller GW, Caron MG, Hen R: Hyperactivity and impaired response habituation in hyperdopaminergic mice. Proc Natl Acad Sci USA. 2001, 98: 1982-1987. 10.1073/pnas.98.4.1982.PubMed CentralView ArticlePubMed
- Barkus C, McHugh SB, Sprengel R, Seeburg PH, Rawlins JN, Bannerman DM: Hippocampal NMDA receptors and anxiety: at the interface between cognition and emotion. Eur J Pharmacol. 2010, 626: 49-56. 10.1016/j.ejphar.2009.10.014.PubMed CentralView ArticlePubMed
- Bannerman DM, Rawlins JN, McHugh SB, Deacon RM, Yee BK, Bast T, Zhang WN, Pothuizen HH, Feldon J: Regional dissociations within the hippocampus--memory and anxiety. Neurosci Biobehav Rev. 2004, 28: 273-283. 10.1016/j.neubiorev.2004.03.004.View ArticlePubMed
- Figueiredo J, Reis A, Vaz R, Leao M, Cruz C: Porencephalic cyst in pycnodysostosis. J Med Genet. 1989, 26: 782-784. 10.1136/jmg.26.12.782.PubMed CentralView ArticlePubMed
- Klose M, Grote K, Lerchl A: Temporal control of spermatogenesis is independent of the central circadian pacemaker in Djungarian hamsters (Phodopus sungorus). Biol Reprod. 2011, 84: 124-129. 10.1095/biolreprod.110.085126.View ArticlePubMed
- Neuhoff V, Philipp K, Zimmer HG, Mesecke S: A simple, versatile, sensitive and volume-independent method for quantitative protein determination which is independent of other external influences. Hoppe Seylers Z Physiol Chem. 1979, 360: 1657-1670. 10.1515/bchm2.1979.360.2.1657.View ArticlePubMed
- Chomczynski P, Sacchi N: Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem. 1987, 162: 156-159.View ArticlePubMed
- Barrett AJ: Fluorimetric assays for cathepsin B and cathepsin H with methylcoumarylamide substrates. Biochem J. 1980, 187: 909-912.PubMed CentralView ArticlePubMed
- Mayer K, Vreemann A, Qu H, Brix K: Release of endo-lysosomal cathepsins B, D, and L from IEC6 cells in a cell culture model mimicking intestinal manipulation. Biol Chem. 2009, 390: 471-480. 10.1515/BC.2009.047.View ArticlePubMed
- Yasuda Y, Kageyama T, Akamine A, Shibata M, Kominami E, Uchiyama Y, Yamamoto K: Characterization of new fluorogenic substrates for the rapid and sensitive assay of cathepsin E and cathepsin D. J Biochem. 1999, 125: 1137-1143.View ArticlePubMed
- Carpenter AE, Jones TR, Lamprecht MR, Clarke C, Kang IH, Friman O, Guertin DA, Chang JH, Lindquist RA, Moffat J, Golland P, Sabatini DM: CellProfiler: image analysis software for identifying and quantifying cell phenotypes. Genome Biol. 2006, 7: R100-10.1186/gb-2006-7-10-r100.PubMed CentralView ArticlePubMed
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.